Drugs / Sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04587947 | Apr 2020 → May 2022 | heart failure | St. Josefs-Hospital Wiesbaden GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/valsartan | “Sacubitril/valsartan (angiotensin receptor-neprilysin inhibitor [ARNI]) reduces cardiovascular mortality and hospitalization for heart failure with reduced ejection fraction.” PMID 39082399 ↗ Jul 2024 |
| Action | Inhibit | “Sacubitril/valsartan is an angiotensin receptor neprilysin inhibitor” NCT04587947 ↗ |